ASA in the News
By Max Savage Levenson for Leafly
“What surprises me the most is when people only care about what’s happening in their own state. We’re a national organization. But what we’ve noticed is that about a year after a law has been passed, suddenly these advocates come out again, and say they don’t have what they need. They start to advocate again.” - Debbie Churgai
Scrutinize the label. You need to know precisely what's within the container. Having this information speaks to the product's purity, quality, consistency and safe use. All this should all appear on product labels, according to "Patient's Guide to CBD: 2019," a downloadable report from Americans for Safe Access, a nonprofit group with the goal of promoting legal, safe use of medical cannabis.
By Louella Losinio for Pacific News Center
Guam received a “C” grade in the recent medical cannabis access state report released by the Americans for Safe Access (ASA). This is an upgrade to the “C-minus” grade Guam received during the previous year.
WSU College of Medicine eyes more instruction on medical cannabis as study suggests doctors reluctant to talk about it - Americans for Safe Access
By Kip Hill for The Spokesman-Review
Washington’s requirement of any type of instruction for its consultants sets it apart from other states that have legalized medicinal cannabis, said Debbie Churgai, interim director of the national group Americans for Safe Access that pushes for reforms to increase clinical access to the drug.
“Most states don’t have required education for doctors, or patients, or anyone that works in a dispensary,” Churgai said. “For Washington state to have that requirement is amazing.”
It's Easier To Buy CBD In Kansas Than To Know For Sure What's In It Or What It's Good For - Americans for Safe Access
By Celia Llopis-Jepsen for KCUR 89.3
“Honestly, I’m scared for people,” said Lisa Sublett, of medical cannabis proponents Bleeding Kansas Advocates. “I don’t trust the stuff at your gas station, sorry. You really have no idea what’s in the bottle.”
She recommends consulting The Patient’s Guide to CBD, a 50-page primer from Americans For Safe Access that explains labels, lab analyses and more.
Medical marijuana users will get dibs if supply wanes, but evidence from other states indicates some may turn to recreational pot once it is legal in Illinois - Americans for Safe Access
By Jamie Munks for the Chicago Tribune
“Anybody who’s really suffering should not be prohibited access to this product.” - David Mangone
University of Maryland School of Pharmacy to offer medical cannabis education - Americans for Safe Access
By Meredith Cohn for the Baltimore Sun
Debbie Churgai, interim director for Americans for Safe Access, said she did not know what changed or why the university did not approach the group again.
The group continues to offer its own courses that focus on how to operate legally and based on what’s known about the science, she said. Churgai said her group initially approached Maryland and persuaded it of the need for well-crafted and standardized training. Maryland could lend credibility and reach far more students, she said.
“We applaud Maryland for finally doing it,” Churgai said about the training. “It would have been nice if they gave us some credit.”
By Kyle Jaeger via Marijuana Moment
“After the momentum of this week between House hearings on cannabis small business access to capital, a [House Veterans’ Affairs Committee] hearing on medical cannabis research, and a historic victory in the House with the Blumenauer CJS amendment, it is incredibly frustrating to see the Congressman withdraw an amendment that would provide medical cannabis access to veterans,” - David Mangone
By Beth Wang for InsideHealthPolicy
Just days after FDA held a 10-hour meeting to discuss the science and regulation of cannabis-based products, Americans for Safe Access issued a resource guide for patients, health care providers, consumers and anyone interested in learning more about cannabidiol (CBD). The guide defines key terminology – including broad spectrum, full spectrum and isolate -- and discusses issues with dosing, two major issues on which FDA officials asked multiple stakeholders to submit more detailed information.
By Billian Flaccus and Angeliki Kastanis for the Associated Press via Yahoo! Finance
"Some of the products that these patients have relied on for consistency — and have used over and over for years — are disappearing off the shelves to market products that have a wider appeal." - David Mangone